Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.

Aconcagua Bio Inc. has divulged calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone and ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

A particular focus is on once-weekly oral GLP-1 and amylin therapies for weight loss. The company’s drug development pipeline centers around harnessing emerging knowledge of gut-brain biology to ...

The other two assets in Verdiva’s pipeline are a once-weekly oral amylin agonist and a long-acting, subcutaneous amylin agonist. The plan is to start a phase 2 study of the GLP-1 agonist this ...

The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. BioWorld ...

Verdiva also has two earlier-stage amylin programs, including one that is orally available and dosed weekly and another that is subcutaneously formulated. Both amylin assets can be used alone or with ...